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Glutathione (GSH) is a tripeptide, which has many biological roles including protection against reactive oxygen and nitrogen
species. The primary goal of this paper is to characterize the principal mechanisms of the protective role of GSH against reactive
species and electrophiles. The ancillary goals are to provide up-to-date knowledge of GSH biosynthesis, hydrolysis, and utilization;
intracellular compartmentalization and interorgan transfer; elimination of endogenously produced toxicants; involvement in
metal homeostasis; glutathione-related enzymes and their regulation; glutathionylation of sulfhydryls. Individual sections are
devoted to the relationships between GSH homeostasis and pathologies as well as to developed research tools and pharmacological
approaches to manipulating GSH levels. Special attention is paid to compounds mainly of a natural origin (phytochemicals)
which aﬀect GSH-related processes. The paper provides starting points for development of novel tools and provides a hypothesis
for investigation of the physiology and biochemistry of glutathione with a focus on human and animal health.
1.Introduction
Glutathione(GSH)isatripeptide(L-γ-glutamyl-L-cysteinyl-
glycine) with multiple functions in living organisms [1–
4]. As a carrier of an active thiol group in the form of a
cysteine residue, it acts as an antioxidant either directly by
interacting with reactive oxygen/nitrogen species (ROS and
RNS, resp.) and electrophiles or by operating as a cofactor
for various enzymes [5–8]. Glutathione is moderately stable
in the intracellular milieus because intracellular peptidases
can cleave peptide bonds formed by the α- c a rb o x y lgr o u p so f
amino acids, but typically not the γ-carboxyl groups.
The reduced and oxidized forms of glutathione (GSH
and GSSG) act in concert with other redox-active com-
pounds (e.g., NAD(P)H) to regulate and maintain cellular
redoxstatus[9].Theformerisquantitativelydescribedbythe
redox potential, calculated according to the Nernst equation.
Inmostcellsandtissues,theestimatedredoxpotentialforthe
GSH/GSSG couple ranges from −260mV to −150mV (cited
after [10]).
GSH is synthesized in a two-step process catalyzed by
L-glutamate: L-cysteine γ-ligase, (γGLCL, EC 6.3.2.2) (also
called γ-glutamyl-L-cysteine ligase or γ-glutamylcysteine
synthase), and glutathione synthase (GLS, EC 6.3.2.3).
GSH is consumed in many ways, such as by oxidation,
conjugation, and hydrolysis [11]. GSH can be directly
oxidized by ROS and RNS or indirectly during GSH-
dependent peroxidase-catalyzed reactions. Conjugation with
endogenous and exogenous electrophiles consumes a sub-
stantial portion of cellular GSH. In addition, cells may lose
GSH due to export of its reduced, oxidized or conjugated
forms. Extracellularly, GSH can be hydrolyzed by γ-L-
glutamyl transpeptidase (GGT, EC 2.3.2.2) transferring the
γ-glutamyl functional group to water during hydrolysis to
form free glutamate [12]. The enzyme may also transfer the
γ-glutamyl moiety of GSH to amino acids and peptides.
Frequently, products of GSH hydrolysis are taken up by
cells either as individual amino acids, or as dipeptides.
The intra- and extracellular GSH levels are determined
by the balance between its production, consumption, and
transportation. Due to important physiological functions of
GSH, these processes are tightly regulated. The activities of
the enzymes involved in GSH metabolism are controlled2 Journal of Amino Acids
at transcriptional, translational, and posttranslational levels
[3, 11].
Since GSH participates not only in antioxidant defense
systems,butalsoinmanymetabolicprocesses,itsrolecannot
beoverestimated.Therefore,itisnotsurprisingthattheGSH
system has attracted the attention of pharmacologists as a
possible target for medical interventions. The main eﬀorts
in this ﬁeld have been applied to decreasing or increasing
GSH levels in organisms. General strategies involve speciﬁc
inhibition of γGLCL, a key enzyme of GSH biosynthesis,
and depletion of cellular reserves by externally added
electrophiles (usually for research purposes). The use of
buthionine sulfoximine (BSO) is probably the most popular
approach to depleting GSH. BSO was ﬁrst synthesised as the
D,L-form [13, 14] and later as the L-BSO enantiomer [15].
Usually a mixture of D- and L-BSO is used in experiments
[16–18]. GSH levels may be enhanced by supplementation
with precursors, mainly cysteine in the form of diﬀerent
esters. However, during the the last decade a new approach
for the regulation of GSH-utilizing enzymes has emerged. It
is evident that many of these are induced at the transcrip-
tional level by mild oxidative stress, which involves binding
of the Nrf2 transcription factor to the antioxidant response
element(ARE)(alsocalledtheelectrophileresponseelement;
EpRE) in the promoter region of genes encoding certain
enzymes, particularly γGLCL and glutathione S-transferases
[19–22].
Glutathione has several additional functions in cells. For
example, it is (i) a reserve form of cysteine, (ii) stores and
transports nitric oxide, (iii) participates in the metabolism
of estrogens, leukotrienes, and prostaglandins, the reduction
of ribonucleotides to deoxyribonucleotides, the maturation
of iron-sulfur clusters of diverse proteins, (iv) involved in the
operation of certain transcription factors (particularly those
involved in redox signalling), and (v) the detoxiﬁcation of
many endogenous compounds and xenobiotics [11].
The present review will focus on the molecular mech-
anisms of operation of the GSH system, with special
attention to regulatory pathways controlling the expression
of the enzymes involved. Information on GSH biosynthesis,
hydrolysis and utilization, intracellular compartmentaliza-
tion, and interorgan transfer will be highlighted. Special
sections will deal with GSH functions, such as antioxidant
properties and relationship to speciﬁc enzymes. On the basis
of these mechanisms, some potential approaches for medical
interventions will also be evaluated.
2. GlutathioneBiosynthesis, Hydrolysis,
Excretion,andUtilization
Intracellular GSH concentrations usually range from 0.5 to
10mM, whereas extracellular values in animals are one to
three orders of magnitude lower [2, 11]. GSH is commonly
the most abundant low molecular mass thiol in animal
and plant cells. Most microorganisms also possess GSH in
high concentrations, but there are some species and viable
mutants lacking GSH [23–25].
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Figure 1: Glutathione is a tripeptide: L-γ-glutamyl-L-cysteinyl-
glycine. In its reduced form (a) the N-terminal glutamate and
cysteinearelinkedbytheγ-carboxylgroupofglutamate,preventing
cleavage by common cellular peptidases and restricting cleavage to
γ-glutamyltranspeptidase.Thecysteineresidueisthekeyfunctional
component of glutathione, providing a reactive thiol group that
plays an essential role in its functions. Furthermore, cysteine
residues form the intermolecular dipeptide bond in the oxidized
glutathione molecule (b).
Figure 1 shows the chemical structure of reduced and
oxidised glutathione forms. GSH is formed from gluta-
mate, cysteine, and glycine (Figure 1(a)), but it possesses
an unusual peptide bond. The N-terminal glutamate and
cysteine residues are linked by the γ-carboxyl group of
glutamate, rather than the common linkage in proteins of an
α-carboxylpeptidebond.Thisspeciﬁcpeptidebondprevents
GSH from being hydrolyzed by most peptidases that cleave
at the α-carboxyl peptide bond of N-terminal amino acids.
This conﬁguration also restricts the cleavage of GSH by GGT
localized on the external surface of certain cell types. As a
result, GSH is relatively stable in the cell and is cleaved by
GGTonlyatexternalsidesonthemembranesofcertaincells.
In addition, the presence of the C-terminal glycine residue in
theGSHmoleculeprotectsitagainstcleavagebyintracellular
γ-glutamyl cyclotransferase. The major oxidized form of
glutathione(i.e.,glutathionedisulﬁde,GSSG)consistsoftwo
residues of GSH that have been oxidized in such a fashion
as to be connected by an intermolecular disulﬁde bond
(Figure 1(b)).
The steady-state level of cellular GSH is provided by the
balance between production and consumption, as well as by
extrusion from the cell as reduced, oxidized, or bound forms
(summarized in Figure 2). GSH is produced in two steps.
In the ﬁrst step, the enzyme γGLCL forms a peptide bondJournal of Amino Acids 3
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Figure 2: Glutathione homeostasis involves both intra- and extracellular mechanisms. Glutathione is synthesized in both de novo and
salvage synthesis pathways. De novo synthesis requires the three amino acids and energy in the form of ATP. Glutamate may be provided in
part from the conversion of a γ-glutamyl amino acid to 5-oxoproline, which is then converted to glutamate. Two ATP molecules are used for
the biosynthesis of one GSH molecule. Salvage synthesis involves either reduction of GSSG or uses precursors formed from the hydrolysis
of GSH or its conjugates by γ-L-glutamyl transpeptidase at the external surface of the plasma membrane that are transported back into the
cell as amino acids or dipeptides. GSH is consumed in various processes. In addition to detoxiﬁcation of reactive species and electrophiles
such as methylglyoxal, GSH is involved in protein glutathionylation and several other processes, such as the biosynthesis of leukotrienes and
prostaglandins, and reduction of ribonucleotides. Modiﬁed from [27].
between the γ-carboxyl of glutamate and the amino group of
cysteine using energy provided by the hydrolysis of ATP:
γ-L-Glutamate + L-cysteine + ATP
−→ γ-L-glutamyl-L-cysteine+ ADP + Pi
(1)
In the next step, the dipeptide is combined with glycine
by glutathione synthetase (GLS), again driven by the hydrol-
ysis of ATP:
γ-L-Glutamyl-L-cysteine + glycine + ATP
−→ GSH + ADP + Pi
(2)
It should be noted that, in some cases, the provision of
ATP for GSH synthesis can be a limiting factor for GSH
metabolism [26]. The ﬁrst step, catalyzed by γGLCL, is the
rate-limiting step for overall GSH biosynthesis process. The
enzyme is inhibited by GSH, the end product of the pathway,
indicating that its biosynthesis is regulated via a negative
feedback control mechanism.
GSH may be oxidized directly by oxidants such as
hydroxyl radical (HO•)[ 28, 29] or peroxynitrite (ONOO−)
[30, 31]. Direct oxidation leads to the production of thiyl
radicals [32], the fusion of which results in GSSG formation
(Figure 2). GSH is extensively used as a cosubstrate by glu-
tathione peroxidases (GPx, EC 1.11.1.9) reducing hydrogen
peroxide (H2O2) or organic peroxides (generally abbreviated
as ROOH or LOOH in the case of lipid peroxides) with the
production of GSSG, water, or alcohols. Figure 3 shows the
dismutation of H2O2 by catalase.
How do catalases and GPxs cooperate in H2O2
catabolism? Firstly, they are mainly localized in diﬀerent cel-
lular compartments—GPxs are cytosolic residents, whereas
catalases are found mainly in peroxisomes. Secondly, the
aﬃnity of GPx for H2O2 is one to two orders of magnitude
higher than that of catalase. So, one may conclude that the
two enzymes operate in concert, complementing each other.
GSSG produced from the consumption of GSH can be either
restoredagainbytheactionofglutathionereductase(GR,EC
1.6.4.2) (reaction (3)), or excreted from the cell.
GSSG + NADPH + H+ −→ 2GSH + NADP+ (3)4 Journal of Amino Acids
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Figure 3: Involvement of glutathione in elimination of reactive oxygen and nitrogen species. Hydroxyl radical and nitric oxide (after
oxidationtotheNO+ form)orperoxynitritemayinteractdirectlywithGSHleadingtoGSSGformation.Hydrogenperoxidemayberemoved
by catalase or by glutathione peroxidase (GPx). The latter requires GSH to reduce peroxide.
Glutathione excretion from cells is inhibited by methion-
ine [33]. Three forms of glutathione, namely, GSH, GSSG,
and GSH-conjugates, can be excreted into extracellular
spaces. There the conjugates are mainly hydrolysed to diﬀer-
ent components and reabsorbed. However, cysteine residues
usually remain conjugated to xenobiotics and are released by
organismsinfeces.MostglutathioneS-conjugatesaremetab-
olized to the corresponding N-acetyl cysteine S-conjugates
(mercapturic acids) and released in the urine and bile [34].
Glutamate and glycine residues are usuallyrecovered, but the
cysteine residues remain conjugated and are lost. Both GSH
and GSSG are substrates for the extracellular membrane-
bound enzyme GGT:
GSH+ amino acid −→ γ-glutamyl-amino acid
+ L-cysteinyl-glycine
(4)
GSH + H2O −→ L-glutamate + L-cysteinyl-glycine
(5)
γ-L-Glutamyl transpeptidase cleaves only the γ-
peptide linkage. The enzyme can transfer the γ-glutam-
yl group of GSH, GSSG, or GSH-conjugates onto amino
acid acceptors to form γ-glutamyl peptides and cysteinyl-
glycine (reaction (4)), or to water thereby hydrolyzing GSH
and related compounds to glutamate and cysteinylglycine
(reaction (5)). Cysteinylglycine can be further hydrolyzed
by a dipeptidase to cysteine and glycine. The products,
namely, amino acids and γ-glutamyl amino acids, may be
transported back into cells and used for GSH resynthesis or
other needs. This provides the basis for recycling of excreted
GSH and GSSG (salvage cycle) by the cell of origin or by
other cells [34]. Upregulation of this process provides an
additional mechanism for GSH maintenance in the cell.
3.IntracellularCompartmentalization and
InterorganTransfer
Although GSH is synthesized in the cytosol, it is distributed
to diﬀerent intracellular organelles where it is used in
organelle-speciﬁc functions related to its role in the regu-
lation of cellular redox status. In addition to the cytosolic
pool, GSH functions in somewhat independent pools in the
endoplasmic reticulum (ER), nucleus, and mitochondria. In
most of these compartments GSH is typically found in a
highly reduced state, but in the ER a substantial portion
is oxidised and the ratio [GSH]/[GSSG] may be as high as
3:1, whereas in the cytoplasm the oxidized form is usually
on the order of about 1% of the total or less [35, 36].
In the ER, GSSG is the main source of oxidizing power
that supports the eﬃcient production of the functional
conformation of nascent polypeptides by the formation of
therequiredintramoleculardisulﬁdebondsbetweencysteine
residues. In the nucleus, GSH maintains the appropriate
redox status of the sulfhydryl groups in proteins involvedJournal of Amino Acids 5
in nucleic acid biosynthesis and DNA repair in addition to
standard antioxidant functions. In this compartment, it is
also used in the reduction of ribonucleotides to produce
deoxyribonucleotides by ribonucleotide reductase [37].
About 10–15% of cellular GSH is located in mitochon-
dria. Since mitochondria have a very small volume, the local
GSH concentration in these organelles is usually higher than
that in the cytosol. Of the various subcellular compartments,
most attention has been paid to the mitochondrial GSH
pool (mGSH) because of the close relationship between
mGSH and cell survival that has been demonstrated in
many cases. This topic is covered in an excellent recent
review of Mari et al. [38] and readers are directed to this
review for extensive details. Here, I will mention just a
few important aspects of the mGSH system. As mentioned
above, GSH is synthesized only in the cytosol and is
transported into intracellular organelles. It easily crosses the
outer mitochondrial membrane through porin channels but,
being an anion, cannot diﬀuse across inner mitochondrial
membrane into the matrix. At least two systems are believed
to be involved in GSH import into the mitochondria across
the inner membrane. GSH transport into the matrix must
overcome an unfavourable electrochemical gradient [39–
44]. This is provided by two mitochondrial membrane
carriers [45, 46] that exchange GSH for dicarboxylates
and 2-oxoglutarate (α-ketoglutarate). These two antiport
carriers provide electroneutral exchange of selected anions
across the inner mitochondrial membrane with no charge
transfer. The role of these two mitochondrial GSH carriers
was also evidenced by a reconstitution of recombinant
mitochondrial dicarboxylate carriers into proteoliposomes
[45]. However, it should be noted that during GSH import
the mitochondria lose important intermediates of the Krebs
cycle so that anaplerotic mechanisms may be needed to
replenish these. It should also be noted that GSSG cannot
leavethemitochondriaandthereforeneedstoberegenerated
in the matrix by GR using NADPH (reaction (3)).
In addition to its “classic” functions, GSH plays
organelle-speciﬁc roles in the mitochondria and a few of
them will be mentioned here. Due to the pivotal role of
mitochondria in programmed cell death (apoptosis) as well
as extensive ROS involvement in this process, and adding the
fact that mitochondria produce over 90% of cellular ROS,
the role of GSH in cell protection cannot be overestimated.
GSH may either directly bind some ROS species or serve as
a source of reductive power for certain antioxidant systems.
The inner mitochondrial membrane is particularly rich
in cardiolipin, whereas it is virtually absent from other
membranes and only the outer mitochondrial membrane
contains minor amounts of this phospholipid. When mGSH
levels are compromised, cardiolipin is one of the important
targets of oxidative damage. Due to its unique chemical
structure among phospholipids, cardiolipin confers stability
and ﬂuidity to the mitochondrial membrane. In addition,
cytochrome c is normally bound to the inner mitochondrial
membrane via its association with cardiolipin. By protecting
cardiolipin from oxidative damage, GSH prevents changes
in the physicochemical properties of the mitochondrial
inner membrane that lead to membrane destabilization
and the dissociation of cytochrome c. ROS also induce
an increase in permeability of the internal mitochondrial
membrane for calcium. Enhanced ROS and calcium levels,
acting in concert, may trigger the cell death machinery via
apoptosis or necrosis. Hence, mitochondrial GSH clearly
has an important role in preventing apoptosis triggered by
cytochrome c release from the inner membrane.
Not surprisingly, therefore, a decrease in mGSH levels is
closely associated with certain pathologies in both humans
and animals. This relationship has been described for
hypoxia/reperfusion injury [47, 48], certain liver diseases
such as alcoholic steatohepatitis [49, 50], nonalcoholic
steatohepatitis [51, 52], and liver cirrhosis [53, 54], neuro-
logical diseases such as Alzheimer and Parkinson diseases,
diabetes mellitus and associated complications [55–57].
Many of the abovementioned pathologies are included in
the group of so-called age-related diseases and, therefore,
it is not easy to diﬀerentiate aging as a normal physio-
logical process and age-related or age-induced pathologies.
Harman [58] proposed the oxidative stress theory of aging,
which he later modiﬁed to the mitochondrial theory of
aging [59]. This theory suggested that oxidative damage to
organisms is connected with the progressive accumulation
of oxidized/modiﬁed products of ROS attack that ultimately
determine the lifespan of organisms. Insofar as they are
cornerstones of the oxidative stress and/or mitochondrial
theories of aging, ROS and mitochondrial function are
intimately regulated by GSH and the [GSSG]/[GSH] ratio,
thereby linking these theories of aging to mitochondrial
GSH levels. Other pathologies, such as several diseases of
the lungs (e.g., chronic pulmonary disease, acute respiratory
distress syndrome, neonatal lung damage, and asthma)
and of the immune system are also associated with a
compromised mitochondrial GSH system [60–62]. Finally,
mGSH involvement in combating the toxicity of diﬀerent
xenobiotics, particularly drugs such as cisplatin, is clearly
evident [63–65].
One more important point related to mGSH should also
be mentioned here. The correct analysis of the mitochon-
drial GSH pool is an experimentally complicated issue. To
study this, cells are typically disrupted in order to isolate
mitochondria and this can substantially aﬀect not only
redox status, but also total GSH content. Hence, there is a
need to introduce new techniques for the proper evaluation
of the operation of the mitochondrial GSH system. Some
interesting ideas on this topic can be found in recent studies
by Winther and colleagues [66, 67].
Another important topic is GSH distribution between
diﬀerent organs of animals. Glutathione can be transported
across the plasma membrane, which is the ﬁrst step of a
complicated interorgan transfer network [4, 13]. Liver is the
main source of GSH exported into the blood [68–71]. The
export of GSH and its conjugates from liver cells occurs
via transporters referred to as organic anion-transporting
polypeptides (OATPs), which are generally believed to carry
out electroneutral exchange, in which the cellular uptake
of organic anions is coupled to the eﬄux of anions such
as HCO3
−, GSH, GSSG, and/or glutathione S-conjugates6 Journal of Amino Acids
[72, 73]. Both GSH and GSSG are circulated and are used
to supply other organs, particularly kidney. The production
in liver and export from it are related to GSH functions,
and at least two principles may be implicated. The ﬁrst
one involves epithelial cells that contact with the exterior,
such as intestine and lungs. The primary GSH function
here is directed to detoxiﬁcation of injurious external agents
t op r e v e n td a m a g et ot h eo r g a n i s m .T h e r ei sal a r g eb o d y
of data indicating that this is an important role of GSH
in normal intestinal function. The lungs are exposed to
high oxygen levels and also to inhaled toxins. Alveolar
macrophagesprovideanadditionalROSsourceinthistissue.
Hence, there are multiple reasons for maintaining adequate
GSH levels in lungs. The second principle is related to
high intensity oxygen-based metabolism and detoxiﬁcation
of certain compounds by internal organs. Liver and kidney
areprobablythebestrepresentativesofthisgroup.Theportal
vein brings blood from the intestine to the liver and, if not
detoxiﬁed in the intestine, xenobiotics must be neutralized
by hepatocytes [52, 74–76]. In addition, the liver is an
important biosynthetic organ where ROS are produced in
substantial amounts as side products of energy production
in the mitochondrial electron transport chain or as the
result of biosyntheses involving diverse oxygenases. Kidney
also requires a highly eﬃcient GSH system to perform its
functions [13, 77, 78]. The problems with extracellular GSH
investigation and intertissue transfer are to a large extent
based on inadequate methodology. Since the concentrations
of extracellular GSH are more than an order of magnitude
lower than intracellular levels, correct redox ratios are often
diﬃcult to determine.
4. GlutathioneFunctions
ThechemicalstructureofGSHdeterminesitspotentialfunc-
tions and its broad distribution among all living organisms
reﬂects its important biological role. GSH has been found
in all mammalian cells. Probably most importantly, GSH
is responsible for protection against ROS and RNS, and
detoxiﬁcation of endogenous and exogenous toxins of an
electrophilic nature. Other functions include (i) maintaining
the essential thiol status of proteins and other molecules; (ii)
storageofcysteinereservesbothinthecellandforinterorgan
transfer; (iii) involvement in the metabolism of estrogens,
leukotrienes, and prostaglandins; (iv) participation in the
reduction of ribonucleotides to deoxyribonucleotides; (v)
participationinthematurationofiron-sulfurclustersinpro-
teins; (vi) copper and iron transfer; (vii) signal transduction
from the environment to cellular transcription machinery.
The above-listed GSH functions and a few others will be
covered in this section.
4.1. Elimination of Reactive Oxygen and Nitrogen Species.
GSH is an important antioxidant, directly reacting with
ROS, RNS, and other reactive species, particularly HO•,
HOCl, RO•,R O 2
•, 1O2,a n dO N O O
−, often resulting in
the formation of thiyl radicals (GS•)( Figure 3). GSH is
also involved as an antioxidant in the detoxiﬁcation of
products from ROS-promoted oxidation of lipids such as
malonic dialdehyde and 4-hydroxy-2-nonenal [79, 80], and
probably many other products of ROS interaction with
cellular components [11, 19, 81, 82]. The thiyl radicals
formed from these reactions can also combine with diﬀerent
molecules, as well as with other thiyl radicals leading to
the formation of oxidized glutathione (glutathione disulﬁde,
GSSG) in the latter instance. GSSG is also produced in
reactions catalyzed by GPx (reaction (6)) and glutaredoxins
(reaction (7)):
ROOH + 2GSH −→ ROH+GSSG+H2O (6)
Oxidized glutaredoxin +2GSH
−→ reduced glutaredoxin + GSSG
(7)
GSSG may be either excreted from the cell, or reduced
by GR at the expense of NADPH (reaction (3)). Most of the
reductive power for this reaction is provided by the pentose
phosphateshunt-twomoleculesofNADPHareproducedper
molecule of glucose-6-P that cycle through the pathway. The
ﬁrst and limiting step is catalyzed by glucose-6-phosphate
dehydrogenase (G6PDH, EC 1.1.1.49):
Glucose-6-phosphate + NADP+
−→ 6-phosphoglucolactone + NADPH+ H+ (8)
The second molecule of NADPH is provided by the
next pentose phosphate shunt reaction, catalyzed by 6-
phosphogluconate dehydrogenase (6-PGDH). These two
enzymes are not the only cellular NADPH producers.
NADPH is also formed by NADP-dependent isocitrate
dehydrogenase, malic enzyme, and some others, but it is
widely believed that most cellular NADPH is generated by
the pentose phosphate pathway.
As mentioned above, the glutathione couple GSH/GSSG
is a critically important redox player and together with
other redox active couples, including NAD(P)/NAD(P)H,
FAD/FADH2, regulates and maintains cellular redox status.
The estimated in vivo redox potential for the GSH/GSSG
couple ranges from −260mV to −150mV depending on the
conditions (cited after [10]).
Under normal conditions, when a cell is not stressed,
the processes that generate ROS are well counterbalanced by
antioxidant systems. In this respect, GSH is often considered
to be a key player of the defense system. However, under
various circumstances the steady-state ROS level increases
leading to oxidative damage to the cell, called “oxidative
stress,” the term ﬁrst deﬁned by Sies [83]“ Oxidative stress”
“came to denote a disturbance in the prooxidant-antioxidant
balance in favor of the former.” The deﬁnition was later
expanded to “An imbalance between oxidants and antioxi-
dants in favour of the oxidants, potentially leading to damage,
is termed “oxidative stress”” to emphasize the damage to
certain cellular components [84]. Owing to extensive studies
on oxidative stress and the discovery of many intricacies
related to this phenomenon over the two last decades, theJournal of Amino Acids 7
deﬁnitioncouldbemodiﬁedto“Oxidativestressisasituation
where the steady-state ROS concentration is transiently or
chronically enhanced, disturbing cellular metabolism and its
regulation and damaging cellular constituents”[ 81]. This
deﬁnition underlines the dynamic nature of the processes of
ROSgenerationandelimination,damagetocellularcoreand
regulatory pathways, and potential negative consequences of
enhanced ROS levels either acutely or chronically. If cells are
not capable of coping with the intensity of oxidative stress,
this can culminate in their death via necrosis or apoptosis.
The dynamics of ROS-related processes are shown in
Figure 4. Under control conditions, steady-state ROS levels
ﬂuctuate over a certain range [81, 82, 85]. However, ROS
levels can exceed this range due to an increase in ROS
productioneitherasaresultofinternalphysiologicalchanges
or external induction. If the cellular antioxidant potential is
high enough, acutely increased ROS levels can be quickly
reduced again back to the initial (control) range. But if the
existing antioxidant potential is not capable of eliminating
extra ROS, the cell can increase its antioxidant defenses,
but it will require some time to respond, and this will also
consume energy and important biomolecules (e.g., amino
acids). Upregulation of the antioxidant potential may result
in the restoration of ROS levels back into the initial range,
or due to a prolonged increase in ROS levels the cell may
enter a state of “chronic oxidative stress” (Figure 4). In many
cases, acute oxidative stress has no serious consequences for
organisms, but the chronic state may lead to or accompany
certain pathologies. Oxidative stress is well-documented to
occur, for example, in cardiovascular and neurodegenerative
diseases, diabetes mellitus, cancer, and aging [9, 12, 47, 51,
86–89]. Under some circumstances, ROS levels do not return
to the initial range and the system may be stabilized at new,
higher ROS level referred to as “quasistationary” that occurs
in various pathological states [81]. Interestingly, the opposite
situationofdecreasedROSlevelscanoccurinsomeinstances
andissometimescalled“reductivestress.”However,therehas
been very little investigation of this situation and, therefore,
it will not be further discussed here.
The above short excursion into oxidative stress theory
underscores not only the importance of GSH for ROS
combating in unstressed conditions, but also the augmented
role that GSH must play during oxidative stress. Enhanced
ROS levels may require not only enhanced GSH action to
maintainredoxstatus,butalsoenhancedenergyandmaterial
consumption to replace consumed GSH and/or transport it
to the places where it is needed.
As mentioned above, GSH may be involved in detoxi-
ﬁcation of RNS [6]. For example, nitric oxide (
•NO) was
initially thought to interact directly with GSH to produce
S-nitrosoglutathione (GSNO). However, further investiga-
tion demonstrated
•NO must ﬁrst be converted to NO+
(nitrosonium ion) in an iron- or copper-catalyzed reaction
before reacting with GSH to form GSNO [90, 91]. It should
be noted that GSNO and other nitrosothiols can be used
for storage and transportation of
•N Ob e c a u s ea su n s t a b l e
compounds they can be decomposed easily to generate
•NO
and GSSG.
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Figure 4: The dynamics of reactive oxygen species in biological
systems. Steady-state levels of reactive oxygen species ﬂuctuate over
a certain range under normal conditions. However, under stress
ROS levels may increase or decrease beyond the normal range
resulting in acute or chronic oxidative or reductive stress. Under
some conditions, ROS levels may not return to their initial range
and stabilize at a new quasistationary level.
4.2. Elimination of Endogenously Produced Toxicants. The
role of GSH in detoxiﬁcation of the end products of lipid
peroxidation such as malonedialdehyde and 4-hydroxy-2-
nonenal was mentioned above. Many other toxic metabo-
lites are produced as side-products of the normal cellular
metabolism. For example, methylglyoxal (2-oxopropanal) is
one of these and it can be generated both enzymatically and
nonenzymatically [92, 93]. Glycolysis appears to be the main
source of methylglyoxal where it is produced from triose
phosphates, particularly due to spontaneous decomposition
of glyceraldehyde-3-phosphate [94, 95]. Methylglyoxal toxic-
ity is based on its capacity to interact with any molecule con-
taining free amino groups such as amino acids, nucleotide
bases of nucleic acids, and cysteine residues in proteins [96–
99]. Methylglyoxal and other α-dicarbonyls, in turn, may be
involved in ROS generation. Glutathione acts as a cofactor
in the system of methylglyoxal elimination which consists
of two enzymes called glyoxalases [92, 100, 101]. The ﬁrst
enzyme in this pathway, glyoxalase I (Glo I, EC 4.4.1.5),
catalyses the isomerization of hemiacetal adducts, which are
formed in a spontaneous reaction between a glutathione and
aldehydes such as methylglyoxal:
glutathione + methylglyoxal ←→ hemithioacetal adduct
←→ (R)-S-lactoylglutathione
(9)
The second enzyme, glyoxalase II (Glo II, EC 3.1.2.6),
catalyzes the hydrolysis of the product of the above reaction:
(R)-S-Lactoyl-GSH + H2O −→ D(-)lactic acid + GSH
(10)
This pathway is the main route for methylglyoxal
catabolism in yeasts [3, 95, 102, 103] and mammals [104–
107].
GSH also may be involved in the detoxiﬁcation of
endogenously produced formaldehyde. For example, some8 Journal of Amino Acids
yeasts produce formaldehyde as part of methanol catabolism
[108–111]. The reaction is catalyzed by formaldehyde
dehydrogenase (FaDH, EC 1.1.1.1) which uses GSH as a
cosubstrate:
Formaldehyde + GSH + NAD+ −→ S-formylglutathione
+N A D H+H +
(11)
Formaldehydealsomaybeproducedfromthecatabolism
of certain amino acids and, therefore, reaction (11)m a y
be important for its detoxiﬁcation in animals and plants
[112, 113]. Interestingly, formaldehyde dehydrogenase also
catalyzes the decomposition of S-nitroso-glutathione and it
is not limited to yeasts [24], but also found in plants and
animals [114–117].
4.3. Metal Homeostasis. GSH can interact with certain metal
ions. It contains six potential coordination sites for metal
ion binding such as cysteinyl sulfhydryl, glutamyl amino,
glycyl,andglutamylcarboxylgroups,andtwopeptidebonds.
Among these, the sulfhydryl group possesses the highest
aﬃnityformetalcations,particularlycadmium,copper,zinc,
silver, mercury, arsenic, and lead [118]. The interaction of a
metal ion with the GSH sulfhydryl group can be stabilized
by coordination with other potential binding sites. The most
stable complexes are formed by divalent cations in a 1:2
ratio with GSH. The complexes form spontaneously because
they are thermodynamically favored and the resulting mer-
captides are relatively stable. Several metabolic functions for
these metal-GSH complexes have been proposed: (i) they
can help in the mobilization and transfer of cations between
ligands; (ii) they can serve to transport metal ions across
membranes; (iii) they serve as a source of cysteine, playing a
centralroleinmetalhomeostasis;(iv)theyserveasacofactor
for redox reactions yielding metal compounds with diﬀerent
speciationorbiochemicalforms[118].Theremainderofthis
section focuses only on GSH involvement in the metabolism
of chromium, copper, and iron ions.
G S Hi si n v o l v e di nC r 6+ reduction in many organisms
(reviewed in [82, 119]). GSH-dependent reduction of Cr6+
results in the formation of Cr3+,e ﬀectively converting the
ion from an anionic form (Cr2O7
2− or CrO4
2−) to a cationic
form [82, 120]. Cr6+ in its anion form (associated with
oxygen)isreadilytransportedintocellsvianonspeciﬁcanion
carriers, but Cr3+ as a cation is not so bioavailable and is
believed to be less toxic due to its interaction with many
cellular ligands [121]. Therefore, Cr6+ reduction to Cr3+ can
be characterized as a way to decrease chromium toxicity
[122]. Although Cr6+ can be reduced nonenzymatically,
studies suggest that in cells GSH and GSH-dependent
enzymes, either alone or in concert with ascorbic acid and
cysteine, play an important role in these processes [119, 123–
126]. For example, the inhibition of GR by carmustine
prevented Cr6+ reduction in isolated rat hepatocytes [127].
Nontoxic biological eﬀects of chromium are also associated
with GSH-related transformation of Cr6+. Although it is not
clear how this occurs, these eﬀects are related to the ability
ofchromiumtoaﬀectcarbohydratemetabolismpotentiating
the eﬀects of insulin [128, 129]. It is worth noting that
although Cr3+ is thought to be a regulator of carbohydrate
metabolism,thecapacityofbiologicalsystemstoreduceCr6+
with the participation of the GSH system may be used to
deliver chromium into biological systems.
GSH plays a more speciﬁc and well-documented role in
the metabolism of copper and iron. GSH is believed to be
responsible for the mobilization and delivery of copper ions
for the biosynthesis of copper-containing proteins [118]. In
t h i sc a s e ,G S Hi si n v o l v e di n( i )r e d u c t i o no fC u 2+ to Cu+,
(ii)mobilizationofcopperionsfromstores,and(iii)delivery
of copper ions during the formation of “mature” proteins.
For the last function, Cu2+ must be reduced to Cu+ before
it can be incorporated into apoproteins, and GSH provides
the reducing power [130]. Interestingly, GSH is not only the
carrier for Cu+, but is also involved in copper mobilization
from metallothioneins in a reversible manner. The Cu(I)-
GSH complex is used for copper incorporation into Cu,Zn-
superoxide dismutase (Cu,Zn-SOD) from bovine erythro-
cytes [131] lobster apohemocyanin [132], and blood plasma
albumin [133].
The role of GSH in iron metabolism is not as well
studied. However, by analogy with copper, GSH may be
involved in iron reduction, transportation, mobilization
from diﬀerent stores, and incorporation into certain target
molecules. GSH involvement in iron metabolism in the yeast
S. cerevisiae, has been investigated in details [134]. GSH was
not required for iron adsorption, delivery to mitochondria,
maintenance of mitochondrial Fe,S-proteins, or for their
maturation. However, the maturation of extramitochondrial
Fe,S-proteins required GSH. Although the precise role of
GSH in this process is not clear, GSH involvement in
facilitated transport of components of Fe,S-clusters was
suggested [134].
5. Glutathione Peroxidasesand Transferases
andTheir Regulation
These enzymes play very speciﬁc roles in cellular metabolism
that should be specially highlighted. As mentioned above,
GPx catalyzes the GSH-dependent reduction of many per-
oxides (reaction (6)). GPx enzymes are particularly involved
in the removal of LOOH, thereby terminating lipid peroxi-
dation chain reactions and protecting biological membranes.
Four isoenzymes of GPx have been identiﬁed in mammalian
tissues [135, 136]. The active site of these enzymes contains
a selenocysteine residue which is responsible for the catalytic
activity. Mammalian isoenzymes GPx-1, GPx-2, and GPx-3
reduce H2O2 and peroxides of free fatty acids, whereas GPx-
4 reduces peroxides of phospholipids and cholesterol [137].
Certain glutathione S-transferases (GST, EC 2.5.1.18)
catalyze GSH conjugation with electrophiles, but some
also catalyze the reduction of lipid peroxides and as a
consequence they are also called selenium-independent per-
oxidases [138]. These GSTs do not possess a selenocysteine
residue in their active site. GSTs are an enzyme super-
family responsible for biotransformation of electrophilic
compounds. In this way GSTs protect organisms againstJournal of Amino Acids 9
genotoxic and carcinogenic compounds of both exogenous
(xenobiotics) and endogenous origin. Mammalian GSTs are
organized in multiple classes designed by Greek letters.
Major classes include Alpha, Mu, Pi, abbreviated in Roman
c a p i t a l sa sA ,M ,P .[ 139]. Traditionally, GST activity
is measured with 1-chloro-2, 4-dinitrobenzene (CDNB),
cumene hydroperoxide, or tert-butyl hydroperoxide as the
substrates. Due to selenium-independent GPx activity, α-
c l a s sG S T sc a ne ﬃciently reduce peroxides of free fatty acids
and phospholipids, as well as cholesterol hydroperoxides
[140]. It is worth noting that α-class GSTs can reduce
peroxides of membrane phospholipids without requiring
phospholipase A2-mediated release of the peroxidized fatty
acids from the membrane phospholipids [141,142].The role
of α-GST in peroxide metabolism is highlighted in excellent
reviews of Awasthi and colleagues [140, 143].
By regulating the level of certain electrophiles, GSTs and
GSH may indirectly aﬀect regulatory pathways controlled
by these compounds. For example, 4-hydroxynonenal (4-
HNE) is a well-known product of lipid peroxidation, which
has a key role in stress-mediated signalling. Its steady-state
intracellular level is determined by the balance between
production due to lipid peroxidation and elimination via
various pathways. One of the subgroups of the anionic α-
class of GSTs can utilize 4-HNE as a preferred substrate,
conjugatingittoGSHwithhigheﬃciency[140].Theenzyme
shows a much higher aﬃnity toward 4-HNE than to most
xenobiotics suggesting its critical role in the regulation of
cellular 4-HNE levels. The adduct formed, GS-HNE, is
exported from cells in an ATP-dependent manner by a
primary transport system similar to the system that extrudes
other GSH conjugates [144, 145].
However, GSTs may not only play positive roles in
cell protection against xenobiotics. In certain cases, they
can be responsible for the need to increase the doses of
speciﬁc drugs. For example, in many solid tumors enhanced
resistance to drugs is associated with the increased activity of
GSTs that detoxify xenobiotics [27, 146]. GST was identiﬁed
as a prominent protein in many cases and is overexpressed
in many cancers resistant to several drugs. These GSTs have
been proven to be a viable target for prodrug activation
with at least one candidate in late-stage clinical development
[146].
The activities of GPxs and GSTs, like other antioxidant
enzymes, are regulated in many ways. Most attention has
been paid to their upregulation via speciﬁc regulatory path-
ways involving ROS or electrophiles at certain stages. Many
reviews extensively describe these pathways [147–152], and
here we will describe just a few of them where GSH is known
to be an active participant. OxyR-related regulatory protein
was described in bacteria about 20 years ago (reviewed in
[153–158]). Subsequently, the YAP1/GPx3-regulated system
was found to be responsible for augmentation of antioxidant
potential in yeast [85, 154, 157, 158]. Finally, in animals
the operation of ROS-based regulatory cascades, involving
GSH and GSH-related enzymes, has been identiﬁed. In
this context, the Nrf2/Keap1 system of animals is often
considered to be the most important and ﬁnely controlled
pathway that regulates the activities of antioxidant and phase
II detoxiﬁcation enzymes via interaction with antioxidant
response elements (ARE) in regulatory regions of many of
the genes that encode antioxidant enzymes [21, 159–168]
(the same gene region is also known as the electrophile
response element (EpRE) to designate its involvement in the
cellular response to electrophiles). In animals, the activities
of many phase II detoxifying enzymes, including GSTs
and GPxs, are also upregulated via the Nrf2/Keap1 system.
The dilemma of the simultaneous regulation of GSTs and
antioxidant enzymes was solved when the mechanism by
which the Nrf2/Keap1 system operation was uncovered
(Figure 5). Under normal (nonstressed) conditions Nrf2
protein interacts with Keap1 in the cytosol and is quickly
ubiquitinated followed by the proteasomal degradation.
However, when ROS levels rise, Keap1 is oxidized and
becomes incapable of binding Nrf2. This results in its
migration (possibly related to phosphorylation by certain
protein kinases) into the nucleus. In the nucleus, Nrf2 binds
to the ARE (EpRE) DNA element of target genes together
with a small Maf protein and perhaps with other proteins.
The complex stimulates the expression of target genes,
including those encoding GSTs and antioxidant enzymes.
Clearly, enhanced expression of antioxidants and phase II
detoxiﬁcation enzymes is an important factor in increasing
cellular resistance to xenobiotics. In addition to GSTs, a
key enzyme of GSH-biosynthesis, γGLCL, is also among the
targets of the Nrf2/Keap1 regulatory pathway. Because of its
involvement in the regulation of diverse physiological pro-
cesses, and especially those related to GSH, the Nrf2/Keap1
system has gained attention not only at the basic biological
level, but also from a pharmacological viewpoint.
Detoxiﬁcation of xenobiotics in animals is usually,
but not always, provided by a speciﬁc system consisting
of so-called phase I, phase II, and phase III enzymes.
Phase I enzymes are represented by hydroxylases such as
endoplasmic reticulum members of the cytochrome P450
family,whichintroduceoxygenontomoleculesofhydropho-
bic xenobiotics and endogenous compounds, transform-
ing them in more hydrophilic forms. Phase II detoxi-
ﬁcation enzymes catalyze conjugation reactions that add
glutathione, amino acids, sulphate, glucuronic, acetyl, or
methyl residues to activated xenobiotics. Plasma membrane
antiporters represent phase III detoxiﬁcation; these energy-
dependent pumps export conjugates from the cell, thereby
decreasing their intracellular concentration. Although this
system of nomenclature for the detoxiﬁcation of xenobiotics
can be useful, the classiﬁcation may not always hold for
detoxiﬁcation reactions involving GSH. For example, many
electrophilicxenobioticscanreactdirectlywithGSHwithout
the prior need for activation by phase I enzymes [34].
6. Glutathionylationof CellularSulfhydryls
An increase in cellular levels of mixed disulﬁdes formed
between GSH and protein thiols, a process called glutathi-
onylation, was demonstrated to be caused by oxidative stress
about three decades ago [169–171]. Since that time many
studies of the role of glutathionylation have been carried out.10 Journal of Amino Acids
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Figure 5:OperationoftheNrf2/Keap1systemduringresponsetooxidativestressinanimals.Undernonstressedconditionsthetranscription
factor Nrf2 binds to the Keap1 homodimer. The resulting protein complex can then further complex with Cullin 3 leading to ubiquitination
of Nrf2 followed by proteasomal degradation. Following an oxidative insult or electrophilic attack, Keap1 cannot bind Nrf2 which allows
Nrf2 to diﬀuse into the nucleus and, in concert with small Maf proteins (sMaf), Map and others, Nrf2 binds to the ARE/EpRE elements of
regulatory regions in genes encoding antioxidant or phase 2 detoxiﬁcation enzymes. Nrf2 migration into the nucleus is promoted by at least
three diﬀerent mechanisms: oxidation of Keap thiol groups to form disulﬁdes, modiﬁcation of Keap1 cysteine residues by electrophiles, or
phosphorylation of Nrf2 by protein kinases that, in turn, may be activated by oxidants.
Work from the laboratory of Sies and others implicated the
process in the regulation of the activity of speciﬁc enzymes
andcertainregulatorypathways[6,172–176].Fromthis,glu-
tathionylation was recognised as one of the physiologically
relevant mechanisms of posttranslational modiﬁcation of
certain proteins. Exposure of cysteine residues of proteins to
ROS leads to their oxidation with the consequent formation
of stable sulfenic, sulﬁnic, or sulfonic acid derivatives and
unstable transient forms (Figure 6). Sulfenic acid may be
returned to the original cysteine form by several reductases
([6, 177] and cited therein) whereas sulﬁnic acid can be
reduced only by the speciﬁc action of sulﬁredoxin [178–
181]. It is believed that sulfonic acid cannot be reduced
in living organisms. Cysteine oxidation to sulfenic acid
may be used for ROS sensing and in this case it plays a
positiveroleincelladaptation.However,morefrequentlythe
oxidationmayinhibitcertainproteinsiftheoxidizedcysteine
residues are important for protein function. Therefore, in
addition to direct reduction of sulfenic acid to cysteine,
living organisms possess other ways of dealing with this
moiety (Figure 6). Sulfenic acid residues may interact with
reduced glutathione forming mixed disulﬁdes [182, 183].
This issue is not so straightforward, because formation
of this dithiol can be implicated in the regulation of
some metabolic pathways. Many proteins are subject to
glutathionylation and some of them lose biological activity
as the result, whereas others may be activated [182]. In
human T lymphocytes, Fratelli and colleagues [184]f o u n d
that cell exposure to oxidants (diamide and H2O2)e n h a n c e d
glutathionylation of certain proteins. These included cyto-
skeletal proteins (vimentin, myosin, tropomyosin, coﬁlin,
proﬁlin, and actin), metabolic enzymes (enolase, aldolase, 6-
phosphoglucolactonase, adenylate kinase, ubiquitin-conju-
gating enzyme, phosphoglycerate kinase, triose phosphateJournal of Amino Acids 11
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isomerase and pyrophosphatase), redox enzymes (perox-
iredoxin 1, protein disulﬁde isomerase, and cytochrome c
oxidase), cyclophilin, stress proteins (HSP70 and HSP60),
nucleophosmin, transgelin, galectin, and fatty acid binding
protein. S-Glutathionylation is thought to be one of the
mechanisms preventing ROS-induced irreversible protein
inactivation under oxidative stress insults. During recovery,
GSH residues can be removed from the glutathionylated
proteins resulting in restoration of their functional activity.
Figure 6 shows the known pathways of glutathionyla-
tion/deglutathionylation and oxidation of cysteine residues
in cellular processes. The routes leading to the formation of
mixed disulﬁdes are interactions between: (i) sulfenic acid
derivativesandGSH,(ii)GSSGandproteincysteineresidues,
(iii) protein cysteine residues and glutathione sulfenate, and,
ﬁnally(iv)proteincysteineresiduesandglutathionedisulﬁde
S-oxide. Connected to the protein via a disulﬁde bond,
GSH can be removed via a thiol-disulﬁde exchange reaction.
GSH is used by glutaredoxin releasing GSSG. It is now clear
that glutathionylation as a posttranslational modiﬁcation of
proteins can be involved in the regulation of the activity of
diverse proteins.
In addition to formation of mixed thiols with proteins,
GSH may also form mixed disulﬁdes with low molecular
mass thiols. In many cases, the biological relevance is
uncertain, but in the case of coenzyme A the formation
of the mixed disulﬁde may be biologically important. For
example, CoASSG was found to inhibit GR [185], phospho-
fructokinase [186], and fatty acid synthase [187], whereas
fructose-1,6-bisphosphatasewasactivated byCoASSG [188].
A very potent vasoconstrictory eﬀect of CoASSG has also
been described [189].
GSTs also play regulatory roles in many cellular processes
in ways that are not usually directly related to their catalytic
activity. Frequently their direct interaction with certain
regulatory enzymes/proteins has been shown to be involved
in cellular responses to oxidative stress, regulation of pro-
liferation, diﬀerentiation, and apoptosis. Most information
on these mechanisms is associated with the pi-type GSTs
(GSTπ). For example, GSTπ inhibits c-Jun aminoterminal
kinase (JNK) [183]. JNK phosphorylation activates c-Jun
and triggers activation of multiple downstream eﬀectors
related to proapoptotic signalling and certain cytotoxicities
but its sequestration in a complex with GSTπ blocks these
events. Under oxidative or nitrosative stresses the above
complex dissociates, and GSTπ undergoes glutathionylation
with subsequent oligomerization. The GSTπ isoenzyme is
believed to be the main isoenzyme involved in this eﬀect,
although other soluble isoforms of GST may also be involved
i nt h i st y p eo fr e g u l a t i o n[ 183].
The glutathionylation process is thought to be
responsible for the anticancer eﬀect of PABA/NO [O2-{2,4-
dinitro-5-[4-(N-methylamino)benzoyloxy]phenyl}1-(N,N-
dimethylamino)diazen-1-ium-1,2-diolate] [190]. Overex-
pression of GSTπ in solid tumors is linked to the
development of resistance to a number of anticancer
agents. PABA/NO is catalytically activated by GSTπ releasing
•NO that elicits antitumor activity both in vitro and in vivo12 Journal of Amino Acids
[191]. Locally produced
•NO extensively modiﬁes speciﬁc
target proteins, particularly protein disulﬁde isomerase
(PDI). Nitrosylation or glutathionylation of PDI leads to
enzyme inactivation, activation of the unfolded protein
response (UPR), and cancer cell death. It has been suggested
that
•NO itself may not be directly responsible for the
toxicity of PABA/NO, but rather that peroxynitrite, which
is much more reactive, provides the eﬀect. Peroxynitrite
is a product of the interaction between nitric oxide and
superoxide anion radical and is known to be a powerful
nitrosating agent [190].
7. Regulation of Transcription of
GSH-RelatedGenes
Being an important antioxidant either directly, or via GSH-
related enzymes, GSH is a key component in the regulation
of redox homeostasis. It is well known that changes in GSH
levels or deregulation of the redox status are caused or at
least are associated with diverse pathologies and aging. The
most thoroughly investigated cases include cardiovascular
and neurodegenerative diseases, cancer, AIDS, cystic ﬁbrosis,
liver disorders, diabetes mellitus, and associated complica-
tions. Regulation of the activities of GSH-related enzymes
is often considered as a way to prevent or ameliorate the
disease. Several cellular signalling systems are known to
be involved. However, the mostly eﬃcient approaches are
related to the possibility of manipulating GSH biosynthesis
and phase II detoxiﬁcation enzymes. In the former case,
attention is focused on the ﬁrst key enzyme of GSH
synthesis, γGLCL, and in the latter case on GSTs. These
enzymes are mainly regulated at the expression level and
some of the mechanisms involved have been deciphered.
Although it is known that the promoter regions of the genes
encoding γGLCL and GSTs possess binding sites for such
transcriptional regulators as NF-κB, AP-1, AP-2, SP-1, and
others [192–194], most attention has been concentrated on
the Nrf2/Keap1 system [160, 195]. This is connected, at
least partially, to its high sensitivity to eﬀectors relative to
other regulatory systems [81]. The Nrf2/Keap1 system is
responsive to many challenges, particularly to oxidants and
electrophiles. As mentioned above, Nrf2 operates in concert
with an adaptor protein, Keap1, a cytoplasmic resident. In
nonstressed cells the binding of Nrf2 to Keap1 promotes
ubiquitination of Nrf2 followed by proteasomal degrada-
tion. This system is tightly regulated in cells (Figure 5).
Enhanced levels of oxidants or electrophiles, as well as
activation of various protein kinases disrupt the Nrf2/Keap1
association resulting in Nrf2 stabilization and migration into
the nucleus. Therein Nrf2 binds to the ARE/EpRE in the
promoter region of target genes and in concert with small
proteins of the Maf family stimulates their transcription. In
a series of elegant studies several mechanisms that direct
Nrf2intothenucleushavebeendescribed(reviewedin[81]):
(i) oxidation of speciﬁc cysteine residues of Keap1 resulting
in its inability to bind Nrf2, (ii) interaction of nucleophilic
molecules with cysteine residue(s) of Keap1 leading to
the formation of adducts that prevent binding to Nrf2,
(iii) phosphorylation of Nrf2 by diﬀerent protein kinases,
and (iv) ubiquitination of Keap1 followed by proteasomal
hydrolysis (Figure 5).
Deciphering the mechanisms of operation of the
Nrf2/Keap1 system helped to explain various previously
puzzling data on chemoprevention in several disease states.
Chemoprevention has attracted much attention as one of
the most practical and realistic strategies for decreasing
the global burden of diseases related to xenobiotics and
certain oxidants. A mechanistic approach has gained accep-
tance recently because it not only provides the rationale
to reveal potential mechanisms, but it also predicts and
identiﬁes potentially eﬀective chemicals. A broad spectrum
of substances have been reported that exhibit chemopre-
ventive potential, and it is noticeable that many of these
substances were identiﬁed in plants, particularly those that
are medicinal and/or edible. Numerous phytochemicals
derived from fruits, vegetables, grains, spices, and herbs
are capable of aﬀecting certain diseases related to disrupted
GSH homeostasis. Extensive reviews on chemopreventive
phytochemicals have been published. Thus, there is no need
for in depth coverage of this ﬁeld, and interested readers are
directedinsteadtoseveralexcellentrecentreviews[21,22,86,
166, 195–198]. In the present review, discussion will be lim-
ited to well-studied phytochemicals that operate by aﬀecting
the Nrf2/Keap1 system. These have been exceptionally well
discussed by Surh and colleagues [21] and are summarized
in Table 1.
Sulforaphane [1-isothiocyanato-(4R,S)(methylsulﬁnyl)
butane] is an isothiocyanate found in broccoli and other
cruciferous plants. It is a known inducer of genes encoding
phase II defense and antioxidant enzymes including GPx,
GST, and γGLCL [196, 211]. Sulforaphane appears to
modulate upstream MAP kinases, but reliably demonstrated
eﬀects are associated with Nrf2 activation via the direct
modiﬁcation of Keap1 cysteine residue(s) [199]. As an ele-
ctrophile, sulforaphane directly interacts with protein thiols
forming thionoacyl adducts. In addition, sulforaphane
induces structural changes in Keap1 leading to its polyu-
biquitination and proteasomal degradation [200].
Curcumin (diferuloylmethane) is derived from the
rhizomes of turmeric (Curcuma longo). It stimulates the
expression of antioxidant and phase II detoxiﬁcation enzyme
genes in several experimental models [212–214]. Curcumin-
induced expression is also mediated via Nrf2 activation in a
ROS-relatedmanner.ROSactivatePKCandP38MAPkinase
which then have downstream eﬀects by phosphorylation of
Nrf2 [201, 215].
Epigallocatechin gallate (EGCG) is a major active cate-
chin of green tea that exerts antioxidant, anti-inﬂammatory
and chemopreventive properties [86, 216, 217]. It stimulates
Akt, ERK1/2 and P38 MAP kinase leading to Nrf2 phospho-
rylation and its import into the nucleus [202, 218].
Several allyl sulﬁdes, namely, diallyl sulﬁde (DAS), diallyl
disulﬁde (DADS), and diallyl trisulﬁde (DATS) are major
components of garlic that are capable of inducing phase II
detoxiﬁcation enzymes in a Nrf2-dependent manner [203,
204, 219]. DAS transiently increases ROS concentrationsJournal of Amino Acids 13
Table 1: Phytochemicals that are known to activate the Nrf2/Keap1 signalling pathway in human and animal systems with identiﬁed
mechanisms.
Phytochemical
Keap1 Nrf2 References
Oxidation Alkylation Ubiquitination Phosphorylation
Sulforaphane − +? ? [ 199, 200]
Curcumin + −− ?[ 201]
Epigallocatechin gallate +[ 202]
Allyl sulﬁdes ? + [203, 204]
Resveratrol +[ 205]
Capsaicin +[ 206]
(10)-Shogaol + [207]
Lycopene [208]
Carnosol +[ 209]
Xanthohumol + [210]
stimulating, ERK and P38 MAP kinase which phosphorylate
Nrf2 [203, 220].
Resveratrol (trans-3,5,4 -trihydroxystilbene) is a poly-
phenol found in grapes, bilberry, blueberry, other berries,
and other plant species. It exerts antioxidant, anti-inﬂam-
matory, antiaging, and chemopreventive activities aﬀecting
cellular signalling [205, 221, 222]. These activities are
mediated, at least partially, by Nrf2 phosphorylation.
Pungent vanilloids such as capsaicin (trans-8-methyl-
N-vanillyl-6-nonenamide), a major pungent of hot chili
pepper (Capsicum annuum)[ 206, 223], and (10)-shogaol
from ginger (Zingiber oﬃcinale) also activate phase II detox-
iﬁcation enzyme expression in a Nrf2-dependent manner
[207]. The former acts in a ROS-dependent manner via
PI3/Akt mediated Nrf2 phosphorylation, whereas the latter
acts via electrophilic alkylation of Keap1.
Lycopene, a natural carotenoid found in tomato and
tomato products also exerts chemopreventive activity in an
Nrf2-dependent manner [208, 224]. However, there is no
available information on the mechanisms involved. It should
benoted,thatabsorptionoflycopenebytheintestineismuch
more eﬃcient from processed tomatoes than from fresh
tomatoes due to a higher bioavailability in the processed
products [225–227].
Carnosol, an orthophenolic diterpene found in rosemary
(Rosmarinus oﬃcinalis), also enhances the expression of
p h a s eI Id e t o x i ﬁ c a t i o ne n z y m eg e n e si na nN r f 2 - r e l a t e d
manner [228]. Upregulation of ERK, P38 MAP kinase,
and JNK pathways was found to be responsible for the
eﬀects, which potentially show the involvement of Nrf2
phosphorylation [228]. Cinnamaldehyde from dried bark of
Cinnamomum cassia also induced phase II enzyme expres-
sion via Nrf2 translocation into the nucleus [209, 229, 230].
Xanthohumol, a sesquiterpene from hop (Humulus lupulus)
also shows chemopreventive activity, inducing antioxidant
and phase II detoxiﬁcation enzymes [210]. Its action was
linked with Nrf2 activation resulting from the alkylation of
Keap1. Hence, a great variety of diverse agents of natural
origin have been found that activate the Nrf2 signalling
p a t h w a y ,b u ti ti sl i k e l yt h a tm a n ym o r er e m a i nt ob e
discovered.
Many diverse studies on the involvement of Nrf2 and
associated components were discussed above. However, in
our opinion, the authors have not always provided clear
evidence of direct or mediated Nrf2 involvement in the
upregulation in certain systems. Although Nrf2 involvement
could be expected logically, other signalling pathways should
also be investigated. This is especially true when dealing with
natural extracts instead of pure compounds because even a
minor component in the extract may aﬀect the system via
an unidentiﬁed pathway(s) and imitate Nrf2 involvement.
Unfortunately, in many cases the data presented do not
provide deﬁnitive evidence to support the involvement of
Nrf2.
The chemopreventive eﬃcacy of various phytochemicals
that has been demonstrated in cell models frequently
cannot be extrapolated to whole organisms due to low
bioavailability. Only a very small portion of consumed
phytochemicals is absorbed in the gastrointestinal tract,
usually much less than 1% [231, 232]. In addition, there
are often potentially negative eﬀects on organisms due
to supposedly useful phytochemicals. They often activate
the expression of genes encoding phase I detoxiﬁcation
enzymes such as cytochrome P450. This can create problems
because many xenobiotics may be activated by oxidation
mediated by these oxygenases and thereby express their toxic
potential. In this case, the transcriptional activation of genes
encoding these oxygenases would be considered a negative
side eﬀect of phytochemical treatment. In some cases, these
compounds may simultaneously activate the expression of
phase I and phase II enzyme genes, in which case the
ﬁnal result would be unpredictable in many circumstances.
Simultaneous induction of the expression of genes encoding
phase II detoxiﬁcation and antioxidant enzymes may take
place with so-called phase III detoxiﬁcation enzymes which
are membrane pumps providing active extrusion of GSH
conjugates of electrophiles that are formed either sponta-
neously or enzymatically in GST-catalyzed reactions. A ﬁnal
important issue must be emphasized when analyzing eﬀects14 Journal of Amino Acids
due to phytochemicals. Phase II and phase III detoxiﬁcation
enzymes may be responsible for catabolizing certain drugs
(such as drugs used to treat cancer) via conjugation with
GSH and extrusion from cells. This could lead to the need
to increase doses of some drugs to make them eﬀective or
could even result in resistance to the drugs.
The mechanism of induction of phase II enzyme expres-
sion by plant polyphenols has been elucidated by Zoete
and colleagues [233]. They investigated the ability of these
compounds and their synthetic analogs to induce the activity
of NADP(H) quinone reductase (NQ01), a prototypic phase
II detoxiﬁcation enzyme. By using quantum-mechanical
methods the authors calculated the tendency of these
compounds to release electrons by the energy of the highest
occupied molecular orbital (EHOMO). They found that the
smaller the absolute EHOMO of an agent (i.e., the lower
its reduction potential), the stronger its electron donor
property was and the greater its inducer potency. That
allowed inducers to be ranked and led to predictions of
the eﬃciency of inducers based on their reduction potential
[233]. However, it should be noted that the experiments
were carried out in cell culture, which does not take into
account factors such as the absorption and transportation
of polyphenols when they are administered to the whole
organism. However, the approach may give some clues for
the prediction of the biological eﬀects of polyphenols in
regulating the activity of antioxidant and phase II and III
detoxiﬁcation enzymes.
8.Relationship betweenGSHHomeostasis
andPathologies
Elevated ROS levels as well as the presence of diﬀerent
xenobiotics are well-known factors in various pathologies
and aging, but in some cases these relationships are not
straightforward. Many details of GSH involvement in these
processes including regulation of GSH-related enzymes were
discussed above. Therefore,the current sectionwill provide a
general summary as well as highlight some potentially useful
therapeutic avenues.
Figure 7 shows general routes of enhanced ROS levels
and/or the presence of xenobiotics associated with various
pathologies. Elevated ROS levels are a key ﬁnding in many
diseases [234] including cardiovascular and neurodegen-
erative diseases, cancer, diabetes mellitus, and aging [88,
89, 197, 235–237]. ROS concentration may be enhanced
for many reasons of both an internal or external nature,
such as inﬂammation or exposure to xenobiotics. GSH can
interact directly with ROS to reduce their levels and in
this manner delay the development of pathologies. The
potential of various phytochemicals to disrupt this link
between ROS elevation and increased pathology may be
related to the inherent antioxidant activity possessed by
variousplantcomponents.However,potentiallymorepotent
protective eﬀects of phytochemicals may arise from indirect
eﬀects. Since this review is focused on GSH, the ways
in which GSH participates in these processes must be
highlighted. They include (1) activation of GSH biosynthesis
via supplementation of substrates and energy, (2) increased
enzymatic potential to produce GSH and reduce GSSG,
(3) increased activities of detoxiﬁcation enzymes that use
GSH, and (4) activation of routes for extrusion of GSSG
and glutathione S-conjugates from cells. It is clear from this
list that there are several good targets for pharmacological
interventions in pathologies in which oxidative stress may be
a contributing factor.
The uptake of xenobiotics and their interaction with
biomolecules in living organisms depend on various fac-
tors such as their chemical and physical properties, type
of organism, and its physiological state. Here, we will
not focus on speciﬁc aspects, but rather will provide
the general principles of xenobiotic metabolism leading
to pathologies, GSH involvement and potential protective
eﬀects of certain phytochemicals. Some xenobiotics can be
directly autoxidized leading to ROS production and the
potential pathological consequences were described above.
However, most xenobiotics are not autoxidized directly
and contribute to pathology only after transformation via
diﬀerent mechanisms. Many xenobiotics are oxidized by
various endogenous oxygenases with the production of ROS
at this stage. The biotransformed xenobiotics that result
may also have enhanced potential to induce pathology via
direct interaction with cellular constituents due to their
electrophilic nature. Biotransformed xenobiotics may also
undergo autoxidation with concomitant ROS generation.
In order to prevent this scenario, cells utilize phase II
detoxiﬁcation enzymes. GSH plays a prominent role in
this process, either directly conjugating with xenobiotics
or participating as a substrate in enzymatically catalyzed
conjugation reactions. Finally, conjugates are excreted from
the cell by the phase III detoxiﬁcation system of plasma
membrane active transporters. However, cellular GSH is
not lost to a great extent; most is reclaimed via GSH
salvage processes (Figure 2). This means that extracellular
transpeptidases cleave the conjugates releasing diﬀerent GSH
components which may be reabsorbed by cells and reused
for tripeptide resynthesis. Overall, then, GSH may prevent
the development of pathology related to electrophiles either
by directly interacting with them or in an enzyme-catalyzed
manner. Some phytochemicals also directly interact with
electrophiles, but their action may also be realized through
activation of GSH synthesis/resynthesis and reduction. Acti-
vation of phase II and III detoxiﬁcation enzymes is thought
to be the main route for xenobiotic detoxiﬁcation and
excretion from the organism. Activation of the transcription
of genes encoding enzymes that combat xenobiotics is one of
the main pharmacological strategies for treating xenobiotic-
induced diseases. As described above, the Nrf2/Keap1 sys-
tem, in concert with other signal transduction systems,
regulates the expression of genes encoding many of the
enzymes involved in phase I, II, and phase III xenobiotic
detoxiﬁcation. Some phytochemicals may stimulate phase I
detoxiﬁcation enzymes and also increase cellular potential
fordetoxiﬁcationofdrugs,whichmaycauseeitheradecrease
in sensitivity to the drug or even complete resistance.
This emphasizes the need for a clear understanding of theJournal of Amino Acids 15
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Figure 7: Involvement of glutathione in the detoxiﬁcation of xenobiotics and reactive oxygen species, its relationship with pathological
development and the potential role of diﬀerent phytochemicals. Glutathione is responsible for helping to maintain redox balance by directly
or indirectly interacting with ROS, and is also involved in detoxiﬁcation of electrophiles either via direct interactions or via enzyme-
catalysed conjugation. Certain phytochemicals may aﬀect GSH action on ROS and electrophiles either by directly interacting with ROS
and electrophiles, or by upregulating defensive enzymes.
molecular mechanisms of both drug and phytochemical
action for the development of new medical strategies.
9.Research Tools andPharmacological
ApproachestoManipulateGlutathioneLevels
The role of GSH in the function of living organisms is clearly
reﬂectedbyaphrasecoinedbySies[4]—theterm“inevitable
GSH.” The great importance of GSH has been revealed in
multiple experiments either by depletion or repletion of
cellular GSH reserves.
Cellular GSH reserves can be depleted in at least three
diﬀerent ways—by increasing GSH oxidation, by inhibition
of biosynthesis, or by inactivation of the genes encoding the
enzymes of GSH synthesis. Experimentally, the cellular GSH
pool can be reduced by treatment with diﬀerent oxidants
such as hydrogen peroxide (H2O2), tert-butyl hydroperoxide
[238,239],ordiamide[240,241].In1979,aspeciﬁcinhibitor
of γGLCL was synthesized—buthionine sulfoximine (BSO)
[13, 14], that when introduced into cells depletes GSH
reserves [16, 17, 242]. These approaches have helped
researchers investigate the function of cellular GSH. Since
the use of oxidants to deplete GSH pools in the treatment of
diﬀerent pathologies usually causes many side eﬀects, BSO
was soon tested not only for basic research purposes, but also
for clinical investigations in cancer research. For example,
local BSO application to certain skin cancers may sensitize
them to irradiation [243], drug [244], and photodynamic
[245] treatments.
Frequently used tools in GSH research and therapy are
interventions that increase GSH levels [246]. This is usually
achieved by supplementation with GSH monoesters and
diesters [247–249], GSH precursors such N-acetyl cysteine
(NAC); [250–252]o rα-mercaptopropionylglycine [87, 253].
Importantly, cysteine is not usually utilized as a precursor
presumably due to its toxicity at high concentrations [254].
On the other hand, cysteine in protein-bound form, particu-
larly as a component of whey, has some potential to increase
G S Hl e v e l s[ 255–258]. The above compounds are used as
precursors for GSH biosynthesis, both experimentally and
in some therapies; for example, NAC is broadly used in
therapies that combat HIV [259–261] and other infections
[262–264]. Although used less frequently than NAC, cysteine
precursor in the form of prodrug, 2-oxothiazolidine-4-
carboxylate(OTC),isalsousedtoenhancecellularGSHlevel
[247]. Experimentally, the overexpression of certain genes
involved in GSH production also may enhance its level.
At least one important factor needs to be taken into
account when treatments are used to elevate GSH. It is
well known that many “classic” antioxidants can, under
certain conditions, become prooxidants. These include low
molecular mass antioxidants such as ascorbic acid [265,
266], epigallocatechin-3-gallate [267], α-tocopherol [268],
and retinol [265], as well as antioxidant enzymes such as
superoxide dismutase [269, 270]. Although information on
possible prooxidant properties of GSH is very limited [271–
273], its potential prooxidant eﬀects cannot be ignored.
Virtually all compounds known as antioxidants possess
prooxidant properties [274]; these are two sides of the
same coin. The relationship between pro- and antioxidant
properties depends on the nature of the compound and
speciﬁc conditions.
10. Conclusions and Perspectives:
Glutathione—Two Faced Janus
Pharmacological Target
GSH has a very complicated pattern of involvement in
diverse biological processes. Consequently, any experimental
and clinical intervention should be undertaken with pre-
caution due to the complicated, interrelated, and tightly
regulated networking of living processes. In many cases, any
modiﬁcation of one parameter may result in unpredictable16 Journal of Amino Acids
responsesfromdiverseprocesses.Forexample,atﬁrstglance,
an increased GSH level through supplementation of its esters
may augment defense mechanisms of not only normal cells,
but also of cancer cells, especially considering that cancer
cells may be rather aggressive in sequestering resources. This
can result in a need to enhance the doses of anticancer drugs.
The same ideology can be applied to upregulation of
detoxiﬁcation and antioxidant enzymes. They are frequently
regulated at the transcriptional level via enhanced Nrf2
binding to ARE/EpRE DNA elements. However, in many
cases, phase II and III detoxiﬁcation enzymes are also
responsible for the detoxiﬁcation of anticancer drugs and
their extrusion from the cell. In addition, some inducers
of these enzymes aﬀect phase I detoxiﬁcation enzymes,
which frequently may transform procarcinogens to actual
carcinogens via metabolic activation by hydroxylases such as
cytochrome P450.
However, taking into account the potential undesirable
eﬀects of pharmacological interventions, there is a need to
investigate them carefully and many diﬀerent models may
be used for that purpose. Based on available information,
some speciﬁc molecules with expected properties can be
synthesized and tested. Several important notes should be
provided in this case. Many potential eﬀectors can exist
in several forms and chemical synthesis may lead to the
production of, for example, mixtures of diﬀerent racemates
or diastereoisomers, some of which may be pharmaceutically
eﬀective, but others of which may cause deleterious eﬀects
suchaswhatoccurredwiththalidomide.Oneofitsracemates
was teratogenic [275]. The second important consideration
in the chemical synthesis of putative drugs is related to the
production of intermediates and side products, which needs
special attention and investigation.
Another important factor should be reiterated here.
Innumerable studies have shown that GSH is an antioxidant.
However, virtually any antioxidant can, under certain condi-
tions, act as a prooxidant [274]. For example, in studies with
yeast we found that superoxide dismutase may act either as
an anti- or prooxidant depending on its expressed activity
[269, 270]. Under certain conditions GSH also can be a
prooxidant [276]. Therefore, precaution should be paid to
interventions that enhance GSH levels.
Because of the above caveats, modern pharmacology
research has refocused on natural products, mainly of plant
origin, although bacteria, fungi, and animal sources cannot
be ignored. The ideal situation is when these components
are possessed by edible vegetables, fruits, herbs, and spices or
products formed during their processing. Excellent examples
of these include sulforaphane from cruciferous plants [196,
211], epigallocatechin gallate from green tea [86, 216, 217],
curcumin from turmeric [201, 212–215], allyl sulﬁdes from
garlic [203, 204, 219, 220], anthocyanins and resveratrol
from diﬀerent berries and grapes [196, 205, 221, 222], and
carnosol from rosemary [228]. These and other examples
demonstrate the great potential for discovery of natural
compounds that can be used as pharmaceuticals that may
aﬀect GSH homeostasis.
Careful selection of experimental models is very impor-
tant. Cell cultures are extremely useful for the identiﬁcation
of potential drugs. They allow rapid testing of diverse
potential compounds at low cost. This approach is especially
helpful for revealing molecular mechanisms of investigated
processes. In some cases, simpler cellular models such as
bacteria and unicellular yeasts can also be used as models,
but in many cases their pathways of xenobiotic catabolism
are very diﬀerent from those of mammals thereby limiting
their use. However, all isolated cell systems have at least
two serious limitations. The ﬁrst is that isolated cells are
not under systemic control by the whole organism, lacking
factors such as the regulatory eﬀects of endocrine and
nervous systems, which may substantially modify cellular
responses. The second is that chemicals or mixtures for
testing are applied directly to cells, which avoids complicated
wholeorganismprocessessuchasabsorpton, transportation,
transformation, and excretion. These processes can lead to
large diﬀerences in the responses of isolated cells versus cells
in intact organisms, emphasizing the fact that both basic
and applied studies must ultimately rely on the use of whole
animal models.
Animal models also have some limitations, both tech-
nical and ethical. The second is beyond the scope of this
review, and, therefore, we will focus only on the ﬁrst
item. First, animal experimental models are much more
expensive and require many more resources than cellular
models. Certainly, mammalian models are the most valuable
because these animals are closest to the human condition.
However, much information may be gained from simple
animal models that may be ultimately applied to mammals.
The fruit ﬂy, Drosophila melanogaster, is one of the most
popular and tractable animal models. Although it is an
invertebrate, it is easy to care for, thousands of diﬀerent
strains exist, and it is possible to manipulate its genome. As
a result several experimental models of human pathologies
have been developed in D. melanogaster, making it a very
useful biomedical tool. Many biological processes and their
regulation are highly conserved in eukaryotes, particularly
from yeasts through insects and to vertebrates. For example,
the Nrf2/Keap1 system has recently been described in D.
melanogaster [277]andﬁsh[278].Warm-bloodedmammals,
such as rats, mice, and primates are also extremely useful
subjects, but ethical issues often substantially limit the use
of mammalian models. As a result, cellular models are
often preferred to animal models. Certainly, clinical trials in
human populations are the ﬁnal step before introduction of
certain drugs.
One more aspect which is frequently ignored should be
highlighted here. This is the problem of accurate measure-
ment of the levels of diﬀerent glutathione forms, particularly
reduced (GSH) and oxidized (GSSG) forms, their ratio (an
index of redox potential), and mixed thioethers need further
experimental development. This is very important because
these parameters are used to characterize the development of
oxidative or nitrosative stresses under some circumstances,
particularly in certain pathologies [9, 10, 27, 146]. When
dealing with cell cultures or unicellular organisms it is
practically impossible to isolate cells from the cultivation
media and ﬁx GSH level quickly. Other problems exist
when studying multicellular organisms. One is the needJournal of Amino Acids 17
for very rapid dissection and freezing of target tissues
because the redox state in cells can change very rapidly.
Another is the fact that many organs consist of multiple
cell types which can possess diﬀerent glutathione levels
and forms. In other words, global analysis of the whole
tissue may give incorrect assessments of glutathione status
in diﬀerent cell types. Finally, there is an issue of the
intracellular distribution of glutathione and its metabolites.
Disintegration of the cell to isolate subcellular components
may result not only in glutathione redistribution, but alter
the redox ratio of reduced to oxidized forms, that is, redox
potential. New approaches, particularly to resolve in vivo
glutathione quantiﬁcation, are needed to solve these and
related problems.
Therefore, a scheme for investigation of potential chem-
icals, pharmaceuticals, or phytochemicals that target GSH
homeostasis may be proposed. At the ﬁrst stage of investi-
gation, cell cultures and unicellular organisms can be used
to identify potential candidate compounds and potential
eﬀectors and, if possible, to identify mechanisms involved.
Selected compounds would then be evaluated at the whole
organism level. Studies with D. melanogaster are easy and
cheap to perform, and existing or specially produced ﬂy lines
with deleted regulatory/eﬀector systems may be tested to
provide further clues as to the biological action and side-
eﬀects of the candidate compound. Zebraﬁsh (Danio rerio)
also can be used as an alternative genetically tractable model
organism, the genome of which has been sequenced, and
many tools for molecular interventions in this organism
have been developed. Indeed, there are reliable data on
the possibility of manipulating the Nrf2/Keap1 system in
these ﬁsh [279]. If successful in these organisms, candidate
compounds of interest may then be studied in mammalian
models. The development of molecular biological tools and
production of lines with deleted genes or chimeric lines may
also provide some additional information. Research with
genetically transformed mice would provide the most useful
information, but they are expensive and time consuming to
work with. So, the ﬁnal strategy would depend on many
circumstances and rely on the facilities available, particular
interests, skills and experience of reserchers.
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